Spironolactone in the treatment of hypertension: a neglected molecule

Česká verzia

Authors: Jiří Veselý
Authors place of work: Kardiologická ambulance Edumed s. r. o., Broumov
Published in the journal: Vnitř Lék 2018; 64(7-8): 815-820
Category: Actualities

Summary

Spironolactone, a mineralocorticoid receptor antagonist, is used in the treatment of hypertension for over 50 years. Due to the absence of morbidity and mortality studies, it is not considered to be a first-choice drug in the treatment of patients with primary hyperaldosteronism. However, it has a secure and stable position in the treatment of resistant hypertension. The effect of spironolactone on blood pressure lowering in antihypertensive combination therapy was demonstrated in several uncontrolled trials. The analysis of ASCOTBPLA study also contributed significantly to this area. In the last 10 years, the higher antihypertensive effect of spironolactone compared to placebo (ASPIRANT) and other antihypertensive drugs (PATHWAY-2) was proved in several randomized studies. The outcomes of morbidity and mortality studies in patients with chronic heart failure are also important for the clinical use of spironolactone in patients with hypertension – spironolactone reduces morbidity and mortality in patients with reduced ejection fraction and morbidity only in patients with normal ejection fraction. The outcomes of above-mentioned clinical studies are reflected in current guidelines in which spironolactone has an indisputable role in the treatment of resistant hypertension, primary hyperaldosteronism, and heart failure with reduced ejection fraction.

Key words:

current guidelines – heart failure – hypertension – resistant hypertension – spironolactone

Zdroje

Cífková R, Bruthans J, Adámková V et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. Cor Vasa 2011; 53(4–5): 220–229.
Horký K, Küchel O. Užití spirolaktonu v terapii městnavé srdeční slabosti. Sborník lékařský 1963; 65(7): 209–220.
Wolf RL, Mendlowitz M, Roboz J et al. Treatment of hypertension with spironolactone. JAMA 1966; 198(11): 1143–1149.
Jeunemaitre X, Kreft-Jais C, Chatellier G et al. Long-term experience of spironolactone in essential hypertension. Kidney Int 1988; 26(Suppl): S14-S17.
Toner JM, Brawn LA, Yeo WW et al. Adequacy of twice daily dosing with potassium chloride and spironolactone in thiazide treated hypertensive patients. Br J Clin Pharmacol 1991; 31(4): 457–461.
Dahlöf B, Sever PS, Poulter NR et al. [ASCOT investigators]. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazid as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005; 366(9489): 895–905. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67185–1>.
Chapman N, Dobson J,Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49(4): 839–845. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000259805.18468.8c>.
Václavík J, Sedlák R, Plachý M et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) – study protocol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155(2): 143–148.
Václavík J, Sedlák R, Plachý M et al. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension 2011; 57(6): 1069–1075. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961>.
Williams B, MacDonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blond, crossover trial. Lancet 2015; 386(10008): 2059–2068. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00257–3>.
Rosa J, Widimský P, Waldauf P et al. Role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized PRAGUE-15 study. Hypertension 2016; 67(2): 397–403. Dostupné z DOI: <http:///dx.doi.org/10.1161/HYPERTENSIONAHA.115.06526>.
Grandi AM, Imperiale D, Santillo R et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40(5): 647–652.
Shah NC, Pringle SD, Donnan PT et al. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007; 25(11): 2345–2351. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e3282e9a72d>.
Sato A, Hayashi K, Naruse M et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41(1): 64–68.
Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone of morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709–717. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199909023411001>.
Pitt B, Pfeffer MA, Assmann SF et al. Spironolactone for Heart Failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383–1392. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1313731>.
[National Institute for Health and Clinical Excellence]. Hypertension: clinical management of primary hypertension in adults. CG127. 2011. Updated 2016. Dostupné z WWW: <http://guidance.nice.org.uk/CG127/Guidance/pdf/English>.
Krause T, Lovibond K, Caulfield M et al. Management of hypertension: summary of NICE guidance. BMJ 2011; 343: d4891. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.d4891>.
Mancia G, Fagard R, Narkiewitz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–357. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc>.
Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart Journal 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>. Erratum in Erratum. [Eur Heart J 2018].
Widimský J, Filipovský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi 2017. Dostupné z WWW: <www.hypertension.cz/sqlcache/navrh-csh-2017-text.pdf>.
Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71(19): e127-e248. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2017.11.006>. Erratum inCorrection. [J Am Coll Cardiol 2018].